As Sanofi's Pompe drug shortage drags on, some patients struggle to access treatments
Source Entity
US Top News and Analysis

Sanofi is facing a prolonged shortage of its Pompe disease treatment, leading to canceled patient infusions and significant health concerns. Patients like Monique Griffin are facing the risk of disease progression due to these critical supply chain disruptions.
The Critical Impact of Sanofi’s Pompe Disease Supply Crisis
A Fragile Lifeline Interrupted
For patients suffering from Pompe disease—a rare, progressive, and often debilitating muscle-wasting disorder—the regularity of enzyme replacement therapy is not merely a medical recommendation; it is a fundamental requirement for survival and mobility. Recent reports indicate that Sanofi, the pharmaceutical giant responsible for producing key treatments for this condition, has been grappling with a persistent supply shortage for over three months. This disruption has left vulnerable patients, such as 51-year-old Monique Griffin, facing the terrifying reality of canceled infusions and the looming threat of physical decline.
The Nature of Pompe Disease and Treatment Dependency
Pompe disease, or acid maltase deficiency, is a genetic disorder that causes the accumulation of glycogen in lysosomes, leading to severe muscle weakness and respiratory failure. Because the body lacks the enzyme necessary to break down this glycogen, patients are entirely dependent on exogenous enzyme replacement therapies to manage their symptoms and maintain quality of life. When these therapies are interrupted, the underlying pathology of the disease begins to manifest rapidly, effectively reversing the progress made through years of treatment. For someone like Griffin, who relies on a wheelchair, the interruption is not just an inconvenience but a direct threat to her functional independence.
Supply Chain Vulnerabilities in Rare Disease Markets
The current crisis highlights a broader, systemic vulnerability within the pharmaceutical industry: the fragility of supply chains for orphan drugs. Unlike mass-market medications, treatments for rare diseases are often produced in smaller quantities with highly specialized manufacturing processes. When these localized supply chains face shipping delays or production bottlenecks, there are few, if any, alternatives for the patients involved. The fact that this shortage has dragged on for months suggests a significant failure in contingency planning, leaving patients in a state of constant anxiety as they await updates on their next scheduled dose.
Corporate Responsibility and Patient Advocacy
Sanofi, a company that positions itself as an innovator in the global health space—as evidenced by its high-profile presence at events like the Viva Technology conference—faces a significant reputational and ethical challenge. While the company has acknowledged the shipping delays, the gap between corporate communication and the lived reality of patients is widening. For those whose health is 'at risk' due to these missed doses, the promise of innovation is secondary to the immediate, practical need for medication. This situation underscores the tension between large-scale pharmaceutical operations and the acute needs of rare disease communities.
Future Trends and the Need for Resilient Distribution
Looking ahead, this event serves as a cautionary tale for the pharmaceutical industry regarding the necessity of supply chain resilience. As more specialized genetic and enzyme-based therapies enter the market, manufacturers must prioritize redundant distribution networks to prevent such life-altering disruptions. If Sanofi and similar organizations cannot ensure the reliability of their supply chain, the trust of the patient advocacy groups and the medical community will inevitably erode. Addressing this crisis is not just a logistical hurdle; it is a moral imperative to prevent the preventable deterioration of patients who rely on these treatments to navigate their daily lives.